CTRI/2022/11/047326进行中（未招募）未知
A randomized, double blind, placebo controlled clinical study to evaluate the safety and efficacy of JUVECOL K in improving skin health
aturetech Co., Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Ambulatory, male and female subjects of 40-60 years age with a Body Mass Index (BMI) of 20 to 29 kg/m2.
- •2. Subjects considered as healthy by Principal Investigator through medical history and laboratory results during screening.
- •3. Female subjects of childbearing potential must be using a medically acceptable form of birth control. Female subjects of non-childbearing potential must be amenorrheic for at least 1 year or had a hysterectomy and/or bilateral oophorectomy.
- •4. Fitzpatrick Skin Photo types III to V
- •5. Subject free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the face.
- •6. Subjects voluntarily agree to participate, sign written informed consent and comply with study protocol.
- •7. Subjects willing not to undergo Skincare therapy, Laser therapy, Botox/Filler, ETC during the study period.
- •8. Subjects willing to not to take food that could effect on skin condition and continue their normal diet during the study period
- •9. Subjects who are having 3-6 degrees wrinkles in the crowâ??s-feet area, with global photodamage score between 3 and 6, and water content 170 or less on both left and right cheeks.
排除标准
- •1. Subjects underwent treatment for COVID-19 within last 3 months or tested positive during the study will be excluded.
- •2. Expectation of any surgery during the study period.
- •3. Subject with history of allergies to cosmetics, pharmaceutical products, or foods containing ingredients included in the study supplement.
- •4. Use of topical retinoids, any other anti-wrinkle steroid products and cosmetic products containing AHA, BHA within the 3 months prior to initiation of the study.
- •5. Subjects who are using moisture-rich cosmetic products within the2 weeks prior to study initiation.
- •6. Subjects with uncontrolled Diabetes (FPG >126 mg/dL) and Hypertension (Systolic > 140 mmHg and Diastolic >90 mmHg).
- •7. Subjects with history of renal or liver impairment, any endocrine, inflammatory, cardiovascular, gastro-intestinal, neurological, psychiatric, neoplastic or metabolic disease.
- •8. Subjects suffering from COPD or having history of any respiratory or breathing disorders.
- •9. Subjects with HIV Positive status.
- •10. Alcohol intake >2 standard drinks per day or use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) and smokers.
- •11. Participation in any other trials involving investigational or marketed products within 30 days prior to the screening visit.
- •12. Clinically significant or abnormal laboratory results during screening.
- •13. Any condition judged by the investigator to be unsuitable for participation in the study.
- •14. Female subjects, who are pregnant, breast feeding or planning to become pregnant during the study period.
研究者
相似试验
已完成
不适用
A clinical study to assess effect of an herbal product in improving testosterone levels in healthy young malesCTRI/2018/11/016337aila Nutraceuticals120
已完成
不适用
Effect of LN22197 in healthy subjects with sleep disturbance due to mild to moderate musculoskeletal discomfortCTRI/2022/09/045855aila Nutraceuticals60
已完成
不适用
Clinical trial to evaluate the efficacy and safety of investigational product (MXP22) on liver health.CTRI/2022/06/043558Synergia Life Sciences Pvt Ltd59
招募中
不适用
This is a mono-center study wherein the efficacy and safety of formulation for vitality, vigour, sexual well-being will be studied in adult male patients.CTRI/2020/05/025286Sami Labs Limited
招募中
不适用
To evaluate efficacy of Cyperus rotundus containing Stilbenes for weight management in obese individuals.CTRI/2022/09/045790Sami Sabinsa Group Limited